Related Experiment Video
Updated: Aug 5, 2026
10:55
Rescue of Recombinant Newcastle Disease Virus from cDNA
Published on: October 11, 2013
Challenges, Advances, and Future Directions in Nipah Virus Vaccine Development
Hongshan Xu1, Xuanxuan Zhang1, Shuai Shang2
1National Institutes for Food and Drug Control, Beijing 102629, China.
Vaccines
|July 27, 2026
Summary
Nipah virus (NiV) poses a severe public health threat with no approved vaccines. This review details advances in NiV vaccine antigen design and platform technologies, proposing regulatory strategies for rapid deployment.
Area of Science:
- Virology
- Vaccinology
- Public Health
Background:
- Nipah virus (NiV) is a highly pathogenic zoonotic virus causing recurrent epidemics in Asia.
- NiV infection has a high case fatality rate (40-100%) and poses a significant public health risk.
- Currently, no licensed human vaccines or specific therapeutics are available for NiV.
Purpose of the Study:
- To systematically review breakthroughs in NiV vaccine antigen design.
- To comparatively analyze the clinical progress of various NiV vaccine platforms.
- To discuss adaptive regulatory science strategies for NiV vaccine development and deployment.
Main Methods:
- Review of scientific literature on NiV vaccine research.
- Focus on antigen design strategies: stabilized prefusion F protein, chimeric G/F antigens, and nanoparticle vaccines.
- Comparative analysis of viral vector, mRNA, and subunit vaccine platforms.
Main Results:
- Significant progress in conformational stabilization of NiV prefusion F protein.
- Development of chimeric G/F antigens and multivalent nanoparticle vaccine strategies.
- Analysis of clinical progress across different vaccine platforms indicates potential.
Conclusions:
- Accelerating NiV vaccine development requires innovative antigen design and platform technologies.
- Regulatory pathways need adaptation due to NiV's sporadic nature and high mortality.
- Strategies like unified correlates of protection and optimized Animal Rule implementation are crucial for rapid vaccine translation and stockpiling.
Related Concept Videos
01:23Vaccine Production
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
01:25Inhibitors Of Virion Release
Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
01:29Microorganisms in Medicine and Therapeutics
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
01:29Respiratory Syncytial Virus Disease
Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
01:19Inhibitors of Virion Maturation and Assembly
As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...